Conditions
Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Pancreatic Ductal Adenocarcinoma
Clinical Trials
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
CLINICALTRIALS.GOV IDENTIFIER
NCT04976634
EudraCT Number
2020-005007-40
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Pancreatic Ductal Adenocarcinoma
Age Range
18+
Sex
All
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about